Why Vertex Pharma Popped, As A Key Rival Plummeted 90%
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (9)
- Sionna Therapeutics stock falls 92% after SION-719 trial failure qz.com · 20h ago
- Sionna Therapeutics stock plunges nearly 100% after cystic fibrosis drug fails key trial The Business Journals · 20h ago
- SION Stock On Track For Worst Day Ever After 90% Drop Yahoo Finance · 20h ago
- Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low Barron's · 1d ago
- Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial STAT · 1d ago
- Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex Fierce Biotech · 1d ago
- Sionna Won’t Advance Add-On Drug After CF Trial Misses Goal Stock Titan · 1d ago
- Sionna Therapeutics shares collapse 92% after cystic fibrosis trial misses key endpoint Yahoo Finance · 1d ago
- Why Vertex Pharma Popped, As A Key Rival Plummeted 90% Investor's Business Daily · 1d ago broke it first
Related trends
Why Nvidia Is Trying To Develop The World’s Best Open-Source AI Models
Nvidia has launched the Nemotron 3.5 Lightning open-source AI model while also working on larger Nemotron 4 models.
Trump media company announces a massive loss and new turnaround effort
Trump Media & Technology Group reports a second-quarter loss of $238 million amid declining digital assets and falling cryptocurrency values.
Wall Street giants partner with Nvidia on $500bn AI financing deal
A $500 billion AI financing pact linking Nvidia with Wall Street giants is dominating business news today.
Defaults Expose Cracks in High-Flying Private Credit
Private‑credit markets clash with optimism as Bloomberg touts rebounds while WSJ warns loan health is deteriorating.
Volkswagen Atlas Cross Sport (2027)
Volkswagen rolls out a more powerful 2027 Atlas Cross Sport, yet omits hybrid tech and even basic towing capacity.
Lenders scrutinize US data center financing as community opposition builds
Lenders now price community pushback as a credit risk in U.S. data center financing, reshaping investor strategies.